 |
|
|
|
 |
Genetic Variates of Response to Cisplatin/Vinblastine/Temozolomide Therapy in Patients with Metastatic Melanoma
[Protocol 09-017]
- Full Title :
- GENETIC VARIATES OF RESPONSE TO CISPLATIN, VINBLASTINE, AND TEMOZOLOMIDE (CVT) IN PATIENTS WITH METASTATIC MELANOMA
- Purpose :
CVT is a combination of three drugs (cisplatin, vinblastine, and temozolomide) that has been shown to shrink tumors in up to 40 percent of patients with melanoma. The purpose of this study is to identify genetic factors that may predict which types of tumors are most likely to respond to CVT chemotherapy.
Researchers will test genes in the tumors of patients with metastatic melanoma who are receiving CVT therapy to see which genes are turned on and which are turned off. They hope this information will help them predict which patients are most likely to benefit from this treatment.
- Eligibility :
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a confirmed diagnosis of metastatic melanoma or recurrent stage III melanoma that has not been treated with prior chemotherapy.
- Patients who have had prior anti-CTLA4 monoclonal antibody treatment must have been off treatment for at least 4 months and have signs of progression of disease.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- Patients must be age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Paul Chapman at 646-888-2378.
|
|
|
|
|
